Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: Which instrument we need?

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 519-527

  Colloca, Giuseppe ^a   Colloca, Pasquale ^b  

^a ASL 1 Imperiese   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Prostate cancer; Quality of life; Questionnaires; Randomized controlled trials

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; HEALTH STATUS; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOMATOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COST OF ILLNESS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 79960339423     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9495-2     Document Type: Article

References (82)

1. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 3 581 592 17287242 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D (Pubitemid 46359643)
2. IF Tannock R de Wit WR Berry J Horti A Pluzanska KN Chi, et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 1502 1512 15470213 10.1056/NEJMoa040720 1:CAS:528:DC%2BD2cXot1Kmu7s%3D (Pubitemid 39315317)
3. DP Petrylak CM Tangen MH Hussain PN Lara Jr JA Jones ME Taplin, et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 1513 1520 15470214 10.1056/NEJMoa041318 1:CAS:528:DC%2BD2cXot1Kmu7c%3D (Pubitemid 39315318)
4. P Marquis B Arnould C Acquadro WM Roberts 2006 Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons Drug Develop Res 67 193 201 10.1002/ddr.20077 1:CAS:528:DC%2BD28Xnt1OlsLg%3D (Pubitemid 44099979)
5. SD Fossa N Aaronson F Calais da Silva L Denis D Newling G Hosbach, et al. 1989 Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer Eur Urol 16 335 339 2476317 1:STN:280:DyaL1Mznsl2ksw%3D%3D (Pubitemid 19214893)
6. T Fujimura S Takahashi H Kume T Takeuchi T Kitamura Y Homma 2009 Cancer-related pain and quality of life in prostate cancer patients: assessment using the Functional Assessment of Prostate Cancer Therapy Int J Urol 16 522 525 19383037 10.1111/j.1442-2042.2009.02291.x
7. G Sandblom P Carlsson K Sennfalt E Varenhorst 2004 A population-based study of pain and quality of life during the year before death in men with prostate cancer Br J Cancer 90 6 1163 1168 15026796 10.1038/sj.bjc.6601654 1:STN:280:DC%2BD2c7jtlChtg%3D%3D (Pubitemid 38496808)
8. MS Litwin DP Lubeck ML Stoddard DJ Pasta SC Flanders JM Hennings 2001 Quality of life before death for men with prostate cancer: results from the CaPSURE database J Urol 165 3 871 875 11176489 10.1016/S0022-5347(05)66547-0 1:STN:280:DC%2BD3M3jtlaqug%3D%3D (Pubitemid 32156298)
9. GY Melmed L Kwan K Reid MS Litwin 2002 Quality of life at the end of life: trends in patients with metastatic prostate cancer Urology 59 1 103 109 11796290 10.1016/S0090-4295(01)01457-1 (Pubitemid 34059315)
10. PW Sullivan PM Mulani M Fishman D Sleep 2007 Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer Qual Life Res 16 571 575 17294287 10.1007/s11136-006-9156-2 (Pubitemid 46474953)
11. Bradley C. Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes. 2006. doi: 10.1186/1477-7525-4-78. (Pubitemid 44741186)
12. B Rosenfeld AJ Roth S Ghandi D Penson 2004 Differences in health-related quality of life of prostate cancer patients based on stage of cancer Psycho-oncol 13 11 800 807 10.1002/pon.797 (Pubitemid 39549579)
13. D Prezioso R Bartoletti M Cecchi V Cicalese SC Cunico R Damiano, et al. 2007 Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study Arch It Urol Androl 79 99 103 (Pubitemid 350073478)
14. DT Eton SJ Lepore VS Helgeson 2001 Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors Cancer 92 1451 1459 11745222 10.1002/1097- 0142(20010915)92:6<1451::AID-CNCR1469>3.0.CO;2-R 1:STN:280: DC%2BD3MnpsFKitA%3D%3D (Pubitemid 32947829)
15. N Balderson T Towell 2003 The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support Br J Health Psychol 8 125 134 12804328 10.1348/135910703321649114 (Pubitemid 36565913)
16. A Caraceni RK Portenoy 1999 An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain Pain 82 263 274 10488677 10.1016/S0304- 3959(99)00073-1 1:STN:280:DyaK1Mvhs1Orsg%3D%3D (Pubitemid 29369094)
17. C Zaza N Baine 2002 Cancer pain and psychosocial factors: a critical review of the literature J Pain Symptom Manage 24 526 542 12547052 10.1016/S0885-3924(02)00497-9 (Pubitemid 36120428)
18. JR De Leeuw A de Graeff WJ Ros GH Blijham GJ Hordijk JA Winnubst 2000 Prediction of depressive symptomatology after treatment of head and neck cancer: the influence of pre-treatment physical and depressive symptoms, coping, and social support Head Neck 22 799 807 11084641 10.1002/1097-0347(200012)22: 8<799::AID-HED9>3.0.CO;2-E
19. JB Epstein S Elad E Eliav R Jurevic R Benoliel 2007 Orofacial pain in cancer: part II-clinical perspectives and management J Dental Res 86 506 518 10.1177/154405910708600605 1:STN:280:DC%2BD2szhtleitw%3D%3D
20. Fischer DJ, Villines D, Kim YO, Epstein JB, Wilkie DJ. Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer. 2009. doi: 10.1007/s00520-009-0712-5.
21. FJ Keefe AP Abernethy LC Campbell 2005 Psychological approaches to understanding and treating disease-related pain Annu Rev Psychol 56 601 630 15709948 10.1146/annurev.psych.56.091103.070302 (Pubitemid 40300798)
22. AK Wahl T Rustoen B Rokne A Lerdal O Knudsen C Miaskowski, et al. 2009 The complexity of the relationship between chronic pain and quality of life: a study of the general Norwegian population Qual Life Res 18 971 980 19688608 10.1007/s11136-009-9515-x
23. CS Cleeland 2007 Symptom burden: multiple symptoms and their impact as patient-reported outcomes J Natl Cancer Inst Mono 37 16 21 10.1093/ jncimonographs/lgm005
24. U.S. Department of Health and Human Services FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes. 2006. doi: 10.1186/1477-7525-4-79. (Pubitemid 44698229)
25. D Cella DS Tulsky G Gray B Sarafian E Linn A Bonomi, et al. 1993 The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 3 570 579 8445433 1:STN:280: DyaK3s7oslKqsQ%3D%3D (Pubitemid 23071057)
26. D Osoba B Zee J Pater D Warr D Kaizer J Latreille 1994 Psychometric properties and responsiveness of the EORTC Quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Qual Life Res 5 555 567
27. JE Brazier R Harper NMB Jones A O'Cathain KJ Thomas T Usherwood, et al. 1992 Validating the SF-36 health survey questionnaire: new outcome measure for primary care Br Med J 305 160 164 10.1136/bmj.305.6846.160 1:STN:280: DyaK38zos1Wgug%3D%3D
28. H Schipper J Clinch A McMurray M Levitt 1984 Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation J Clin Oncol 2 472 483 6374052 1:STN:280:DyaL2c3hsFahtw%3D%3D (Pubitemid 14075981)
29. R Rabin F de Charro 2001 EQ-5D: a measure of health status from the EuroQol Group Ann Med 33 337 343 11491192 10.3109/07853890109002087 1:STN:280:DC%2BD3MvksFWqsw%3D%3D (Pubitemid 32675374)
30. P Esper 1997 Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument Urology 50 920 928 9426724 10.1016/S0090-4295(97)00459-7 1:STN:280:DyaK1c%2FovVWgsg%3D%3D (Pubitemid 28021111)
31. G van Andel A Bottomley SD Fossa F Efficace C Coens S Guerif, et al. 2008 An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer Eur J Cancer 44 2418 2424 18774706 10.1016/j.ejca.2008.07.030
32. MS Litwin RD Hays A Flink PA Ganz B Leake RH Brook 1998 The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure Med Care 36 7 1002 1012 9674618 10.1097/00005650- 199807000-00007 1:STN:280:DyaK1czjslektw%3D%3D (Pubitemid 128456439)
33. T Wei RL Dunn MS Litwin HM Sandler MG Sanda 2000 Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer Urology 56 899 905 11113727 10.1016/S0090-4295(00)00858-X 1:STN:280:DC%2BD3M7hsFCjtw%3D%3D
34. IF Tannock D Osoba MR Stockler DS Ernst AJ Neville MJ Moore, et al. 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1756 1764 8656243 1:CAS:528: DyaK28XjslOrsr8%3D (Pubitemid 26185452)
35. D Osoba IF Tannock DS Ernst AJ Neville 1999 Health-related quality of life in men with metastatic prostate cancer treated with mitoxantrone and prednisone J Clin Oncol 17 1654 1663 10561201 1:CAS:528:DyaK1MXktV2qtL8%3D (Pubitemid 29269233)
36. KE Covinsky AW Wu S Landefeld AF Connors RS Phillips J Tsevat, et al. 1999 Health status versus quality of life in older patients does the distinction matter? Am J Med 106 435 440 10225247 10.1016/S0002-9343(99)00052-2 1:STN:280:DyaK1M3jvFOmsQ%3D%3D (Pubitemid 29190597)
37. CE Ferrans 2007 Differences in what quality-of-life instruments measure J Natl Cancer Inst Mono 37 22 26 10.1093/jncimonographs/lgm008
38. KW Smith NE Avid SF Assmann 1999 Distinguishing between quality of life and health status in quality of life research: a meta-analysis Qual Life Res 8 447 459 10474286 10.1023/A:1008928518577 1:STN:280:DyaK1MvgtlCqtg%3D%3D (Pubitemid 29379029)
39. G Kemmler B Holzner M Kopp M Dunser R Greil E Hahn, et al. 2002 Multidimensional scaling as a tool for analysing quality of life data Qual Life Res 11 223 233 12074260 10.1023/A:1015207400490 1:STN:280:DC%2BD38zjtFCqtQ%3D%3D (Pubitemid 34553503)
40. F Efficace A Bottomley D Osoba C Gotay H Flechtner S D'haese, et al. 2003 Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21 3502 3511 12972527 10.1200/JCO.2003.12.121 (Pubitemid 46594084)
41. F Joly J Vardy M Pintilie IF Tannock 2007 Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer Ann Oncol 18 1935 1942 17698837 10.1093/annonc/mdm121 1:STN:280: DC%2BD2sjktFWhtg%3D%3D (Pubitemid 350286228)
42. K Cocks MT King G Velikova PM Fayers JM Brown 2008 Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials Eur J Cancer 44 1793 1798 18599286 10.1016/j.ejca.2008.05.008
43. G Guyatt H Schunemann 2007 How can quality of life researchers make their work more useful to health workers and their patients? Qual Life Res 16 1097 1105 17530444 10.1007/s11136-007-9223-3 (Pubitemid 47357724)
44. D Cella EA Hahn K Dineen 2002 Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening Qual Life Res 11 207 221 12074259 10.1023/A:1015276414526 (Pubitemid 34553502)
45. LE Braitman 1983 Statistical, clinical, and experimental evidence in randomized controlled trials Ann Intern Med 98 3 407 408 6830083 1:STN:280:DyaL3s7ltV2rtQ%3D%3D (Pubitemid 13158518)
46. Guyatt G, Osoba D, Wu AW, Wyrwich KW, Norman GR, the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clinic Proc. 2002; 77:371-83. (Pubitemid 34260746)
47. De Vet HC, Terwee CB, Ostelo RW, Beckerman H, Knol DL, Bouter LM. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes. 2006. doi: 10/1186/1477-7525-4-54.
48. D Osoba A Bezjak M Brundage B Zee D Tu J Pater, et al. 2005 Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group Eur J Cancer 41 280 287 15661554 10.1016/j.ejca.2004.10.017 (Pubitemid 40126961)
49. CM Moinpour GW Donaldson MW Redman 2007 Do general dimensions of quality of life add clinical value to symptom data? J Natl Cancer Inst Mono 37 31 38 10.1093/jncimonographs/lgm007
50. CM Moinpour GW Donaldson Y Nakamura 2009 Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial Qual Life Res 18 147 155 19130298 10.1007/s11136-008-9433-3
51. RP Abratt D Brune MA Dimopoulos J Kliment J Breza FP Selvaggi, et al. 2004 Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer Ann Oncol 15 1613 1621 15520061 10.1093/annonc/mdh429 1:STN:280:DC%2BD2crkslSltQ%3D%3D (Pubitemid 39562600)
52. DS Ernst IF Tannock EW Winquist PM Venner L Reyno MJ Moore, et al. 2003 Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 21 3335 3342 12947070 10.1200/JCO.2003.03.042 1:CAS:528:DC%2BD2cXps1akurk%3D (Pubitemid 46613484)
53. PW Kantoff S Halabi M Conaway J Picus J Krishner V Hars, et al. 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study J Clin Oncol 17 2506 2513 10561316 1:CAS:528:DyaK1MXltlyltL8%3D (Pubitemid 29368252)
54. G Hudes L Einhorn E Ross A Balsham P Loehrer H Ramsey, et al. 1999 Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial J Clin Oncol 17 3160 3166 10506613 1:CAS:528: DyaK1MXmslGmtLs%3D (Pubitemid 29470646)
55. D Cella MB Nichol D Eton JB Nelson P Mulani 2009 Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer Value Health 12 124 129 18647260 10.1111/j.1524-4733.2008.00409. x
56. PW Sullivan WF Lawrence Jr V Ghushchyan 2005 A national catalogue of preference-based scores for chronic conditions in the U.S Med Care 43 7 736 749 15970790 10.1097/01.mlr.0000172050.67085.4f (Pubitemid 40993769)
57. CC Gotay 2004 Assessing cancer-related quality of life across a spectrum of applications J Natl Cancer Inst Mono 33 126 133 10.1093/jncimonographs/lgh004
58. J Lipscomb MS Donaldson NK Arora ML Brown SB Clauser AL Potosky, et al. 2004 Cancer outcomes research J Natl Cancer Inst Mono 33 178 197 10.1093/jncimonographs/lgh039
59. JM Blazeby K Avery M Sprangers H Pikhart P Fayers J Donovan 2006 Health-related quality of life measurement in randomized clinical trials in surgical oncology J Clin Oncol 24 3178 3186 16809741 10.1200/JCO.2005.05.2951 (Pubitemid 46646225)
60. D Osoba 2007 Translating the science of patient-reported outcomes assessment into clinical practice J Natl Cancer Inst Mono 37 5 11 10.1093/jncimonographs/lgm002
61. MI Bennett 2009 The Brief Pain Inventory: revealing the effect of cancer pain Lancet Oncol 10 1020 19796754 10.1016/S1470-2045(09)70114-7
62. TA Rummans MM Clark JA Sloan MH Frosta JM Botswick PJ Atherton, et al. 2006 Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial J Clin Oncol 24 635 642 16446335 10.1200/JCO.2006.06.209 (Pubitemid 46630427)
63. S Cohen 2004 Social relationships and health Am Psychol 59 8 676 684 15554821 10.1037/0003-066X.59.8.676 (Pubitemid 39526342)
64. S Sultan DA Fisher CI Voils AY Kinney RS Sandler D Provenzale 2004 Impact of functional support on health-related quality of life in patients with colorectal cancer Cancer 101 2737 2743 15536617 10.1002/cncr.20699 (Pubitemid 39603181)
65. A Bottomley L Jones 1997 Social support and the cancer patient-a need for clarity Eur J Cancer Care 6 72 77 10.1111/j.1365-2354.1997.tb00271.x 1:STN:280:DyaK2szotFOnsw%3D%3D (Pubitemid 127688352)
66. P Williams L Barclay V Schmied 2004 Defining social support in context: a necessary step in improving research, intervention, and practice Qual Health Res 14 942 960 15296665 10.1177/1049732304266997 (Pubitemid 44526379)
67. P Zaninotto E Falaschetti A Sacker 2009 Age trajectories of quality of life among older adults: results from the English Longitudinal Study of Ageing Qual Life Res 18 10 1301 1309 19806468 10.1007/s11136-009-9543-6
68. D Fitzsimmons J Gilbert F Howse T Young JI Arraras A Brédart, et al. 2009 A systematic review of the use and validation of health-related quality of life instruments in older cancer patients Eur J Cancer 45 19 32 18823775 10.1016/j.ejca.2008.07.036
69. D Cella M Bullinger C Scott I Barofsky 2002 and the Clinical Significance Consensus Meeting Group. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life Mayo Clinic Proc 77 384 392 10.4065/77.4.384 (Pubitemid 34260747)
70. CC Gotay J Lipscomb CF Snyder 2005 Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase J Natl Cancer Inst 97 1568 1574 16264176 10.1093/jnci/dji337 (Pubitemid 41662710)
71. PA Ganz PJ Goodwin 2007 Health-related quality of life measurement in symptom management trials J Natl Cancer Inst Mono 37 47 52 10.1093/ jncimonographs/lgm010
72. MS Donaldson 2004 Taking stock of health-related quality of life measurement in oncology practice in United States J Natl Cancer Inst Mono 33 155 167 10.1093/jncimonographs/lgh017
73. J Greenhalgh AF Long R Flynn 2005 The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Soc Sci Med 60 833 843 15571900 10.1016/j.socscimed.2004.06.022 (Pubitemid 39574779)
74. L Collette G van Andel A Bottomley GON Oosterhof W Albrecht TM de Reijke, et al. 2004 Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group J Clin Oncol 22 3877 3885 15459209 10.1200/JCO.2004.07.089 (Pubitemid 41079868)
75. N Sadetsky A Hubbard PR Carroll W Satariano 2009 Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavour) database Qual Life Res 18 1019 1027 19697155 10.1007/s11136-009- 9526-7
76. C Quinten C Coens M Mauer S Comte MAG Sprangers C Cleeland, et al. 2009 Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials Lancet Oncol 10 865 871 19695956 10.1016/S1470-2045(09)70200-1
77. Emrich LJ, Priore LR, Murphy GP, Brady MF, the Investigators of the National Prostatic Cancer Project. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985; 45:5173-9. (Pubitemid 16236210)
78. SD Fossa E Paus M Lindegaard DW Newling 1992 Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment Br J Urol 69 175 179 1371425 10.1111/j.1464-410X.1992.tb15491.x 1:STN:280:DyaK387mtlOqug%3D%3D
79. SD Fossa 1994 Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience Br J Urol 74 345 351 7524999 10.1111/j.1464-410X.1994.tb16625.x 1:STN:280: DyaK2M%2FktFSmtA%3D%3D (Pubitemid 24276094)
80. B Garssen 2002 Psycho-oncology and cancer: linking psychological factors with cancer development Ann Oncol 13 172 175
81. PN Butow AS Coates SM Dunn 2000 Psychosocial predictors of survival: metastatic breast cancer Ann Oncol 11 469 474 10847468 10.1023/A:1008396330433 1:STN:280:DC%2BD3cvotVGmsQ%3D%3D (Pubitemid 30333552)
82. S Tross J Herndon A Korzun AB Kornblith DF Cella JF Holland, et al. 1996 Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B J Natl Cancer Inst 88 661 667 8627642 10.1093/jnci/88.10.661 1:STN:280:DyaK283hvVyiug%3D%3D (Pubitemid 26152552)